Working… Menu

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01584440
Recruitment Status : Completed
First Posted : April 25, 2012
Last Update Posted : January 11, 2018
Information provided by (Responsible Party):
Avanir Pharmaceuticals

Brief Summary:
The objectives of the study are to evaluate the safety, tolerability and efficacy of AVP-923 compared to placebo, for the treatment of symptoms of agitation in patients with Alzheimer's Disease (AD).

Condition or disease Intervention/treatment Phase
Agitation Alzheimer's Disease Drug: AVP-923 (dextromethorphan/quinidine) Drug: Placebo Phase 2

Detailed Description:

Eligible patients for this study must have a diagnosis of probable AD and must have clinically meaningful agitation secondary to AD.

This is a multicenter, randomized, double-dummy, double-blind, placebo-controlled study, consisting of 10 weeks of treatment.

Up to 200 patients will be enrolled at approximately 30-40 centers in the US.

Study medication will be administered orally twice-daily from Day 1 through Day 70. Screening must occur within within approximately 4 weeks prior to randomization. Following screening procedures for assessment of inclusion and exclusion criteria, eligible patients will be randomized into the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 220 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease.
Study Start Date : June 2012
Actual Primary Completion Date : July 2014
Actual Study Completion Date : September 2014

Arm Intervention/treatment
Placebo Comparator: Placebo Drug: Placebo
Placebo capsules administered twice a day over a 10-week period

Experimental: AVP-923 Drug: AVP-923 (dextromethorphan/quinidine)
AVP-923 capsules administered twice a day over a 10-week period

Primary Outcome Measures :
  1. Neuropsychiatric Inventory (NPI) [ Time Frame: 10 weeks ]
    Primary Endpoint: Agitation/Aggression Domain of NPI

Secondary Outcome Measures :
  1. Safety and Tolerability [ Time Frame: 10 weeks ]
    Standard Measurements (e.g. AEs, ECG, Labs, PE and Neuro Exam)

  2. Neuropsychiatric Inventory (NPI) [ Time Frame: 10 weeks ]
    Total NPI

  3. Neuropsychiatric Inventory (NPI) [ Time Frame: 10 weeks ]
    Caregiver Distress for NPI Domains

  4. Neuropsychiatric Inventory (NPI) [ Time Frame: 10 weeks ]
    NPI-4A (Composite of 4 NPI Domains)

  5. Neuropsychiatric Inventory (NPI) [ Time Frame: 10 weeks ]
    NPI-4D (Composite of 4 NPI Domains)

  6. Neuropsychiatric Inventory (NPI) [ Time Frame: 10 weeks ]
    Individual Domains of NPI

  7. ADCS-CGIC (Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change Rating) [ Time Frame: 10 weeks ]
    Agitation and Overall

  8. PGIC Patient Global Impression of Change (PGI-C) [ Time Frame: 10 weeks ]
    Agitation (Rated by Caregiver)

  9. QoL-AD (Quality of Life - Alzheimer's Disease measure) [ Time Frame: 10 weeks ]
  10. ADCS-ADL (Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory) [ Time Frame: 10 weeks ]
  11. CSI (Caregiver Strain Index) [ Time Frame: 10 weeks ]
  12. CSDD (Cornell Scale for Depression in Dementia) [ Time Frame: 10 weeks ]
  13. (MMSE) Mini-Mental State Examination [ Time Frame: 10 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

Diagnosis of probable Alzheimer's disease (AD).

The patient has clinically significant symptoms of agitation secondary to AD, that interfere with daily routine and for which a prescription medication is deemed indicated, in the opinion of the investigator.

Either out-patients or residents of an assisted-living facility or a skilled nursing home.

CGI-S score is ≥ 4 (moderately ill) at screening and baseline.

Mini Mental State Examination (MMSE) score at screening between 8 and 28 (inclusive).

Caregiver who is able and willing to comply with all required study procedures, ensuring that the patient attends all study visits and takes the study medication as instructed. In order to qualify as a caregiver for this study, the individual should spend time with the patient for a minimum of 4 hours on 4 separate days per week.

Key Exclusion Criteria:

Patient has other type of dementia (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease, substance-induced dementia).

Patients with co-existent clinically significant or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g. malignancy, poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, certain cardiac conduction abnormalities including QTc prolongation, or unstable valvular heart disease).

Patients with myasthenia gravis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01584440

Layout table for location information
United States, Arizona
Phoenix, Arizona, United States, 85006
Sun City, Arizona, United States, 85351
United States, California
Fresno, California, United States, 93720
Fullerton, California, United States, 92835
Los Angeles, California, United States, 90073
Los Angeles, California, United States, 90095
San Diego, California, United States, 92103
San Francisco, California, United States, 94109
Sherman Oaks, California, United States, 91403
Temecula, California, United States, 92591
United States, Florida
Boynton Beach, Florida, United States, 33426
Deerfield Beach, Florida, United States, 33064
Hialeah, Florida, United States, 33012
Miami, Florida, United States, 33122
Miami, Florida, United States, 33137
Miami, Florida, United States, 33173
Ocala, Florida, United States, 34471
Orlando, Florida, United States, 32806
Sunrise, Florida, United States, 33351
Tampa, Florida, United States, 33609
West Palm Beach, Florida, United States, 33407
West Palm Beach, Florida, United States, 33409
Weston, Florida, United States, 33331
United States, Illinois
Elk Grove Village, Illinois, United States, 60007
United States, Nevada
Las Vegas, Nevada, United States, 89106
Las Vegas, Nevada, United States, 89147
United States, New Jersey
Summit, New Jersey, United States, 07902
Toms River, New Jersey, United States, 08757
United States, New York
Orangeburg, New York, United States, 10962
Rochester, New York, United States, 14620
White Plains, New York, United States, 10605
United States, Ohio
Centerville, Ohio, United States, 45459
Cincinnati, Ohio, United States, 45227
Cleveland, Ohio, United States, 44195
Columbus, Ohio, United States, 43221
Lakewood, Ohio, United States, 44107
United States, Pennsylvania
Allentown, Pennsylvania, United States, 18104
Reading, Pennsylvania, United States, 19604
United States, South Carolina
Charleston, South Carolina, United States, 29401
United States, Texas
Houston, Texas, United States, 77030
San Antonio, Texas, United States, 78238
United States, Utah
Salt Lake City, Utah, United States, 84106
United States, Vermont
Bennington, Vermont, United States, 05201
United States, Washington
Spokane, Washington, United States, 99204
Sponsors and Collaborators
Avanir Pharmaceuticals
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Avanir Pharmaceuticals Identifier: NCT01584440    
Other Study ID Numbers: 12-AVR-131
First Posted: April 25, 2012    Key Record Dates
Last Update Posted: January 11, 2018
Last Verified: January 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Psychomotor Agitation
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Neurologic Manifestations
Psychomotor Disorders
Neurobehavioral Manifestations
Antitussive Agents
Respiratory System Agents
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Anti-Arrhythmia Agents
Antiprotozoal Agents
Antiparasitic Agents